Andy Hsieh
Stock Analyst at William Blair
(4.26)
# 1,410
Out of 4,352 analysts
319
Total ratings
46.9%
Success rate
9.4%
Average return
Main Sectors:
Stocks Rated by Andy Hsieh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KLRA Kailera Therapeutics | Maintained: Buy | n/a | $22.84 | - | 3 | May 27, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterated: Buy | n/a | $7.91 | - | 14 | May 26, 2026 | |
| CRDF Cardiff Oncology | Reiterated: Buy | n/a | $1.90 | - | 16 | May 20, 2026 | |
| TNYA Tenaya Therapeutics | Maintained: Buy | n/a | $0.869 | - | 3 | May 15, 2026 | |
| AARD Aardvark Therapeutics | Reiterated: Buy | n/a | $4.11 | - | 5 | May 15, 2026 | |
| PYXS Pyxis Oncology | Reiterated: Hold | n/a | $1.80 | - | 9 | May 14, 2026 | |
| ALT Altimmune | Reiterated: Hold | n/a | $3.05 | - | 10 | May 13, 2026 | |
| AVIR Atea Pharmaceuticals | Reiterated: Buy | n/a | $4.67 | - | 8 | May 13, 2026 | |
| KYNB Kyntra Bio | Reiterated: Hold | n/a | $6.93 | - | 27 | May 12, 2026 | |
| SKYE Skye Bioscience | Reiterated: Buy | n/a | $0.7754 | - | 17 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $17.29 | - | 12 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $64.88 | - | 30 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $39.34 | - | 9 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $44 | $50.48 | -12.84% | 57 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $32.74 | - | 35 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $32 | $20.74 | +54.29% | 1 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $99.30 | - | 13 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $48.74 | - | 3 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.6807 | - | 9 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.26 | n/a | 15 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.68 | n/a | 22 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $134.43 | n/a | 1 | Feb 12, 2019 |
Kailera Therapeutics
May 27, 2026
Maintained: Buy
Price Target: n/a
Current: $22.84
Upside: -
Corbus Pharmaceuticals Holdings
May 26, 2026
Reiterated: Buy
Price Target: n/a
Current: $7.91
Upside: -
Cardiff Oncology
May 20, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.90
Upside: -
Tenaya Therapeutics
May 15, 2026
Maintained: Buy
Price Target: n/a
Current: $0.869
Upside: -
Aardvark Therapeutics
May 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.11
Upside: -
Pyxis Oncology
May 14, 2026
Reiterated: Hold
Price Target: n/a
Current: $1.80
Upside: -
Altimmune
May 13, 2026
Reiterated: Hold
Price Target: n/a
Current: $3.05
Upside: -
Atea Pharmaceuticals
May 13, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.67
Upside: -
Kyntra Bio
May 12, 2026
Reiterated: Hold
Price Target: n/a
Current: $6.93
Upside: -
Skye Bioscience
May 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.7754
Upside: -
May 11, 2026
Reiterated: Hold
Price Target: n/a
Current: $17.29
Upside: -
May 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $64.88
Upside: -
May 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $39.34
Upside: -
May 6, 2026
Reiterated: Buy
Price Target: $44
Current: $50.48
Upside: -12.84%
Apr 29, 2026
Maintained: Buy
Price Target: n/a
Current: $32.74
Upside: -
Apr 29, 2026
Initiated Coverage: Buy
Price Target: $32
Current: $20.74
Upside: +54.29%
Mar 17, 2026
Rated: Buy
Price Target: n/a
Current: $99.30
Upside: -
Mar 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $48.74
Upside: -
Aug 7, 2025
Reiterated: Buy
Price Target: n/a
Current: $0.6807
Upside: -
Dec 22, 2023
Rated: Hold
Price Target: n/a
Current: $1.26
Upside: n/a
Dec 1, 2021
Downgraded: Hold
Price Target: n/a
Current: $1.68
Upside: n/a
Feb 12, 2019
Maintained: Buy
Price Target: n/a
Current: $134.43
Upside: n/a